Late-Breaking Research Orals - 3
Back to course
Video Transcription
Video Summary
Asset Subtitle

Moderator(s): Krzysztof Kiryluk, Laura Mariani

Presentation(s):
  • Safety and Efficacy of Anti-CD19/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor-Natural Killer Cell (CAR-NK) Therapy in Pediatric Patients with Refractory Systemic Lupus Erythematosus (SLE): A Preliminary Clinical Study - Hanyan Meng
  • Farabursen Increases Urinary Polycystin-1 and Polycystin-2 and Reduces Height-Adjusted Total Kidney Volume Growth in Patients with ADPKD - Alan Yu
  • Trial to Evaluate and Assess Effects of Comprehensive Kidney Replacement Therapy (KRT)-Directed, Pre-ESKD Education (CoPE) on Home Dialysis Among Veterans (TEACH-VET): Evaluating KRT Decision-Making State (KDS) Outcomes - Ashutosh Shukla
  • Efficacy and Safety of Povetacicept in Patients with IgAN and Primary Membranous Nephropathy (pMN) at 48 Weeks of Treatment: The RUBY-3 Study - James Tumlin
  • Long-Term Effect of Oral Methylprednisolone on Kidney Outcomes in Patients with IgAN: TESTING-ON, a Post-Trial Observational Study - Muh Geot Wong
  • AHA/ACC Hypertension Guidelines: What's New for Kidney Diseases? - Vivek Bhalla

Note: Continuing education credits are not being offered for this session.
Meta Tag
Date 11/8/2025
Pathway 1 Other
Session ID 527930
Keywords
CAR-NK therapy
anti-CD19/BCMA
pediatric systemic lupus erythematosus
lupus nephritis
faribursen
anti–miR-17 oligonucleotide
autosomal dominant polycystic kidney disease
kidney replacement therapy education (COPE)
povetacicept (BAFF/APRIL inhibitor)
IgA nephropathy
2025 AHA/ACC hypertension guideline CKD